Novel Prognostic Markers in Renal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01002937|
Recruitment Status : Unknown
Verified October 2009 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : October 28, 2009
Last Update Posted : October 28, 2009
|Condition or disease|
|Renal Cell Carcinoma|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples|
|Study Start Date :||December 2008|
|Estimated Primary Completion Date :||March 2011|
|Estimated Study Completion Date :||March 2011|
Tumour tissue, renal cell carcinoma
> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
- The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002937
|Contact: Professor Martin Gorefirstname.lastname@example.org|
|Royal Marsden NHS Foundation Trust||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Principal Investigator:||Professor Martin Gore||Royal Marsden NHS Foundation Trust|